We systematically reviewed the literature on anal, penile, cervical, and oropharyngeal human papillomavirus (HPV) infection in Greece to provide a comprehensive overview of HPV prevalence and to explore the reporting of HPV in Greek men and women. A total of five databases, including PubMed and Scopus, were searched up until 1 January 2015 for studies looking at HPV prevalence, incidence, or risk factors by anatomical site. We identified 50 eligible studies for inclusion. The majority of them were cervical studies (n = 26) followed by head and neck studies (n = 13) with only two studies exclusively focusing on anal sites and two on penile sites. The remaining studies examined prevalence from multiple sites. Most studies looked at small, high-risk populations, and HPV prevalence ranged from 2.5-43.4% for cervical studies; 0-91% for head and neck studies; 54.6-78.4% for anal studies; and 20.3-66.7% for penile studies. Age, smoking, and number of sexual partners were the commonly assessed risk factors. There were significant sex and anatomic site disparities in the reporting of HPV prevalence. Given the relationship between HPV infection and the increasing incidence of anal cancer in men, more research is needed to reveal the prevalence of HPV at these sites in Greek men, especially given the reports of the declining health of the Greek population.
Introduction
Human papillomavirus (HPV) has more than 100 subtypes identified to date, with subtypes classified into lowrisk types (e.g. HPV 6, 11, 42) , which are implicated in anogenital warts in both males and females, and high-risk types (e.g. HPV 16, 18, 31) , which have been linked to cervical cancer and other cancers (Muñoz et al., 2003; CDC, 2014) . Because of the high prevalence of HPV and its association with cervical cancer, there have been numerous studies in Greece focusing on HPV prevalence and risk factors in women. However, growing evidence suggests that HPV can also cause significant disease in men. Not only are HPV-positive men able to transmit the virus to their female sexual partners, but HPV has also been implicated in oropharyngeal cancers, anal cancers, and penile cancer in men (Kreimer et al., 2005; Moscicki and Palefsky, 2011; Nyitray et al., 2014) . The role of HPV in these cancers is especially significant in high-risk populations, including HIV-positive persons or men who have sex with other men (MSM) (Backes et al., 2009; Hoots et al., 2009) . Previous epidemiologic studies have demonstrated a high prevalence of the virus (>12.4%) among low-risk men and an even greater prevalence among high-risk men (30.9%) (Dunne et al., 2006; Hebnes et al., 2014) .
Examining HPV in both women and men in Greece is crucial at this point in time for several reasons. First, the rate of smoking in Greece is one of the highest in Europe (∼40%). Studies have found a correlation between smoking and HPV positivity, which may impact the development of dysplasia and cancer following infection (Kjellberg et al., 2000; Antonsson et al., 2014; Roura et al., 2014) . Second, the recent economic crisis in Greece has resulted in a 50% increase in the incidence rate of HIV infections from 2010 to 2011 (Ifanti et al., 2013) . Overall, the economic crisis has also resulted in a significant increase in the number of people below the poverty line and those reporting severe material deprivation (HS, 2013) . Recent data suggest that increased rates of homelessness are associated not just with increased HIV risk among injecting drug users but also with increased sexually transmitted infection (STI) risk in general (HS, 2013; Tsang et al., 2015) . This economic stress could Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (www.eurjcancerprev.com). jeopardize decision-making or access to STI preventative measures among Greek men and women, especially as condom use has been linked to a reduction in risk of HPV infection (Pierce Campbell et al., 2013) .
For these reasons, we systematically reviewed the literature to identify all articles that have looked at HPV prevalence at cervical, anal, penile, vaginal, and oropharyngeal sites, and in which the sex of participants is reported. To our knowledge there has been no previous systematic review of HPV epidemiology in Greece, which is in contrast with other European countries and the USA where there have been several systematic reviews (Giorgi Rossi et al., 2012; Anderson et al., 2013; Stier et al., 2015) . The objectives of this article are to determine the extent to which previous studies have looked at HPV prevalence in men, to evaulate potential risk factors prevalent in the Greek population, and to provide a comprehensive summary of the current information available on HPV in Greece. We expected to find underreporting of HPV prevalence in Greek men, especially in high-risk men. As the majority of studies included in this review were published before the beginning of the economic crisis, its findings serve as a benchmark upon which future epidemiologic and interventional studies can build to limit HPV transmission among Greek men and women.
Methods
We used the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines for this systematic review (Moher et al., 2010) . The purpose of the PRISMA guideline is to ensure the high quality of systematic reviews and meta-analyses.
Data sources
The database search was carried out up to 1 January 2015, and the following databases were included: PubMed, Scopus, Web of Science, CINAHL, and Cochrane (Fig. 1) . The detailed search strategy used for the PubMed database can be found in Supplementary Appendix A, Supplemental digital content 1 (http://links. lww.com/EJCP/A30) of this review. Similar search strategies were used for other databases.
Study selection and data abstraction
The following were the criteria for study inclusion:
(1) The population included a specific Greek or Greek-Cypriot subset.
(2) Anal, cervical, penile, vaginal, or oropharyngeal HPV infection with risk, incidence, and/or prevalence defined as outcome variables in symptomatic and/or asymptomatic individuals.
(3) Sex of study participants was reported in the manuscript.
(4) Reporting was quantitative and was conducted in part or in whole in Greece. (5) The study was published as a full manuscript in English or Greek.
As we were interested in extracting data on HPV prevalence in the Greek population, we only included studies that reported quantitative data. Moreover, we excluded studies that did not report the sex of the study participants because we were interested in assessing the availability of data on HPV by sex. We did not exclude studies on the basis of date of publication.
After conducting the search and retrieving the articles, two reviewers (S.T., L.H.) independently reviewed the title and abstract of each study to determine whether the inclusion criteria were met and scored the study as 'Include', 'Do not include', or 'Uncertain'. For the studies that were marked as 'Uncertain', the reviewers identified the source of the uncertainty and reviewed the entire article to make a final determination of eligibility ( Fig. 1 ). Senior authors (A.K., J.S.) reviewed a subset of articles, and the differences in decisions around inclusion were resolved as a group. The two reviewers then read through all the studies marked for inclusion and excluded those that did not meet the inclusion criteria upon fulltext review. The following data were abstracted: date of publication, location, study type, number tested, sex distribution, age distribution, sampling location (cervical, anal, etc.), subtype-specific HPV prevalence, and any risk factors assessed.
The studies were then separated on the basis of the location of sampling into cervical, anal, penile, and oropharyngeal, and analyzed separately to determine the range of HPV prevalence reported at these sites for both symptomatic and asymptomatic participants in Greece. Risk factors reported by individual studies were also analyzed in aggregate to determine the most common risk factors for HPV infection.
Quality assessment
Two reviewers (S.T., L.H.) independently went through each article that was to be included in this review and scored them according to a modified risk of bias tool that had been previously reported for assessing bias in systematic reviews of prevalence studies (Hoy et al., 2012) ( Supplementary Table B1 , Supplemental digital content 1, http://links.lww.com/EJCP/A30). The modified risk of bias tool includes 10 items that address four domains of bias in studies and a summary risk of bias assessment (Hoy et al., 2012) . The questions are designed to determine internal validity (five questions) and external validity (five questions). After each reviewer had scored the articles, the inter-rater agreement was calculated and was found to indicate substantial agreement (κ = 0.635). A linear regression was carried out to determine trends in quality over time. The reviewers discussed any differences in ratings and arrived at a consensus ( Supplementary Table B2 , Supplemental digital content 1, http://links.lww.com/EJCP/A30). Moreover, a third reviewer (J.S.) rescored 10% of the articles for quality assurance. All statistical analyses were carried out using STATA, version 13.0 (StataCorp corporation, College Station, Texas, USA).
Results
Overall study characteristics and quality
Our search identified 72 articles that potentially met the inclusion criteria. After reading through the full-text of each article, a total of 50 articles were selected for final inclusion (Fig. 1) . A large proportion of the studies were cross-sectional in nature (n = 24) and were completed at a single hospital or outpatient clinic in Greece. Only three studies were case-control studies and the remainder were either retrospective sample testing or diagnostic studies. Studies generally did not employ a random sampling method, rather they consecutively sampled patients attending a particular clinic during a given time period, or enrolled participants on the basis of availability of archived biopsied tissues. Moreover, the average risk of bias score for the studies was 6.6 out of 10, indicating that the overall quality of the studies was low. Based on linear regression analysis there was a strong, albeit not statistically significant, trend of increasing quality over time (r = 0.238, P = 0.089).
The majority of the studies investigated HPV prevalence in specific groups that cannot be generalized to the larger Greek population. In particular, only seven studies included representative screening populations at multiple sites, but most of these were conducted on women. Moreover, we found that there were a limited number of Articles not meeting screening criteria excluded (n = 588)
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studies looking exclusively at HPV in men. We identified two studies including only men in their sample compared with 30 studies including only women. The remaining studies included both sexes. Interestingly, out of all the studies that included men (n = 20), only two studies specifically reported the distribution of MSM in their population and a single study reported HPV prevalence separately for HIV-positive and HIV-negative men (Gomousa-Michael et al., 2000; Hadjivassiliou et al., 2007; Mavrogianni et al., 2011) . All three of these studies restricted their samples to the anogenital area.
HPV prevalence at cervical sites
We identified 30 studies looking at cervical HPV prevalence in our review, and the majority of them (n = 26) sampled exclusively from a cervical site (Tables 1 and 4 ). In addition to numerous smaller studies of specific populations, nine large studies including at least 1000 patients have been carried out in Greece (Agorastos et al., 2004 (Agorastos et al., , 2009 (Agorastos et al., , 2014 Panotopoulou et al., 2007; Tsiodras et al., 2010 Tsiodras et al., , 2011 Spathis et al., 2012; Argyri et al., 2013a Argyri et al., , 2013b Diamantopoulou et al., 2013) . Six of these larger studies report HPV prevalence rates that range from 15.7 to 43.4% (Panotopoulou et al., 2007; Tsiodras et al., 2010 Tsiodras et al., , 2011 Spathis et al., 2012; Argyri et al., 2013a Argyri et al., , 2013b Diamantopoulou et al., 2013) . The remaining three studies report HPV prevalence rates ranging from 2.5 to 5.9% among asymptomatic women (Agorastos et al., 2004 (Agorastos et al., , 2009 (Agorastos et al., , 2014 . While some of them were conducted at a single hospital or clinic, five of them drew their sample populations from multiple geographic locations (Agorastos et al., 2004 (Agorastos et al., , 2009 (Agorastos et al., , 2014 Tsiodras et al., 2011; Spathis et al., 2012) .
Earlier studies found that the most prevalent HPV strains were typically 16, 6, 11, and 18, which is consistent with prior studies on HPV and the strains included in current HPV vaccines (Lambropoulos et al., 1994; Agorastos et al., 1995; Koffa et al., 1995; Labropoulou et al., 1996; Dokianakis et al., 1999; Diakomanolis et al., 2001; Hassan et al., 2001; Malamou-Mitsi et al., 2002; Prokopakis et al., 2002; Konidaris et al., 2007; Kroupis et al., 2007) . However, more recent large studies using more comprehensive typing methods have demonstrated a high prevalence of such strains as 53, 31, 42, 41, 51, 59, and 35 (Agorastos et al., 2009, 2014; Papachristou et al., 2009; Stamataki et al., 2010; Michala et al., 2012; Argyri et al., 2013a Argyri et al., , 2013b .
Common risk factors assessed by the various studies included age, number of sexual partners, age of sexual debut, income level, and smoking status. The one relationship that remained consistent and significant across studies was the relationship between age and HPV prevalence. Multiple studies found that HPV prevalence was highest in younger women, with prevalence rates declining with increasing age (Agorastos et al., 1995 (Agorastos et al., , 2004 (Agorastos et al., , 2009 Kroupis et al., 2007; Papachristou et al., 2009; Stamataki et al., 2010; Tsiodras et al., 2010 Tsiodras et al., , 2011 Argyri et al., 2013a Argyri et al., , 2013b . Other studies found that multiple sexual partners increased HPV risk (Konidaris et al., 2007; Stamataki et al., 2010; Tsiodras et al., 2011; Michala et al., 2012) . Lastly, smoking, a factor found to be associated with the development of cervical cancer in previous studies, was found to be significantly associated with HPV in only two studies included in this review (Kjellberg et al., 2000; Konidaris et al., 2007; Michala et al., 2012; Roura et al., 2014) .
HPV prevalence at head and neck sites
We identified a total of 13 studies in our systematic review that examined head and neck sites ( Table 2) . Specific anatomic locations included oral mucosa (n = 7), esophagus (n = 2), larynx (n = 2), adenoids/tonsils (n = 2), and parotids (n = 1) (Lambropoulos et al., 1997; Aggelopoulou et al., 1999; Gorgoulis et al., 1999; Bouda et al., 2000; Lyronis et al., 2005 Lyronis et al., , 2008 Mammas et al., 2006 Mammas et al., , 2012 Vageli et al., 2007; Kouvousi et al., 2013; Blioumi et al., 2014; Laskaris et al., 2014; Tsimplaki et al., 2014) . Only five studies included asymptomatic patients (Lambropoulos et al., 1997; Bouda et al., 2000; Lyronis et al., 2005; Lyronis et al., 2008; Blioumi et al., 2014) . The remaining studies focused on testing patients with dysplasia, hyperplasia, or cancer. The number of participants ranged from nine to 258 patients, but was generally limited. Overall, for adult asymptomatic patients, the HPV prevalence at oral sites ranged from 0 to 56%, whereas for adult symptomatic patients it ranged from 11.3 to 91%. The only study that included an asymptomatic screening population found an HPV prevalence rate of 9.5% (Lambropoulos et al., 1997) . This particular study had a low risk of bias and included a wide agerange of patients. Moreover, two studies specifically enrolled children (age range: 2-14) with tonsillar/adenoid hyperplasia, and found prevalence rates of 8.5 and 8.4% (Mammas et al., 2006 (Mammas et al., , 2012 . Interestingly, six studies reported HPV prevalence separately for men and women (Bouda et al., 2000; Mammas et al., 2006; Lyronis et al., 2008; Blioumi et al., 2014; Laskaris et al., 2014; Tsimplaki et al., 2014) . In all of these studies, with the exception of one, women had a higher HPV prevalence than men (Bouda et al., 2000) .
The oropharyngeal studies also identified several risk factors including age, heavy smoking, and alcohol intake. The two studies that specifically enrolled children found that younger age correlated to HPV infection (Mammas et al., 2006 (Mammas et al., , 2012 . This same result was also found by another adult study that examined specimens from patients with oral malignancies and/or dysplasia (Blioumi et al., 2014) . These results seem to conflict with the study that included the asymptomatic screening population and which found that increasing age correlated with higher prevalence (Lambropoulos et al., 1997) . However, this study only looked at asymptomatic patients, and hence 41, 51, 59, 16, 53, 31, 39, 66, 18, 33, 6, 43, 56, 11, 44, 45, 52, 58, 73, 82, 40, 68 Smoking (P = 0.0001), increased number of sexual partners (P = 0.007), inadequate use of contraception (P = 0.027) 7
Spathis et al. , 42, 16, 51, 53, 56, 59, 31, 39, 66, 44, 52, 33, 45, 6, 18, 68, 58, 40, 11, 43, 82, 70, 35, 73 Younger age (P 42, 16, 51, 53, 56, 59, 31, 44, 39, 66, 52, 18, 33, 45, 6, 68, 73, 40. 11. 58, 43, 82, 70, 35 None 7 HPV-age correlation could differ between patients who were asymptomatic and patients who had abnormal cytology. Three studies also found a significant correlation between HPV infection and smoking (Gorgoulis et al., 1999; Bouda et al., 2000; Laskaris et al., 2014) . The major HPV subtypes found in head and neck sites were 6, 16, and 18. However, many studies used techniques that were not able to identify all subtypes; hence, there may be missing data on the actual type-specific distribution of HPV at these sites (Table 2) .
HPV prevalence at anal sites
To our knowledge only four studies on the prevalence of HPV at anal or perianal sites have been carried out in Greece up to this point in time (Tables 3 and 4 ) (Labropoulou et al., 1994; Mavrogianni et al., 2011; Valari et al., 2011; Alexandrou et al., 2014) . One study enrolled patients with perianal warts and included a high-risk population (Mavrogianni et al., 2011) . The overall prevalence was found to be 78.4%, which is much higher than that reported by other studies in Europe and the USA (Dunne et al., 2006) . The study also reported that MSM with perianal warts were more likely to develop intraanal warts compared with non-MSM. Another study that was of particular interest looked at women with suspected cervical, vulvar, or vaginal HPV-related pathology, and studied HPV positivity at both cervical and anal sites (Valari et al., 2011) . They found that cervical pathology was associated with anal HPV infection and concluded that women with abnormal colposcopy findings may also be at risk for anal malignancies.
HPV prevalence at penile sites
A total of five studies investigated the prevalence of penile HPV in Greek men (Tables 3 and 4 ) (Labropoulou et al., 1994; Gomousa-Michael et al., 1997 Hadjivassiliou et al., 2007; Yapijakis et al., 2008) . One study, which looked at men visiting a dermatologist for penile lesions, stratified its participants on the basis of HIV status, and it was the only one to do so among all the studies included in this systematic review (Gomousa-Michael et al., 2000) . HPV prevalence was higher in HIV-positive men compared with HIVnegative men (66.7 vs. 50%). A second study included a larger population of 550 men with genital warts and 64 asymptomatic men with HPV-positive female partners (Hadjivassiliou et al., 2007) . The reported prevalence rate was higher (50.9%) for the patients with genital warts than it was for the asymptomatic patients (20.3%). The study included 56 MSM participants who were found to be more likely to be HPV positive compared with non-MSM (P < 0.001) (Hadjivassiliou et al., 2007) . Another study in this category enrolled high-risk women and their male sexual partners who had abnormal urethral cytology (Gomousa-Michael et al., 1997) . The sites sampled included the penile urethra for men and the cervix for women. The study reported a synchronous HPV infection in 50% of sexual partners indicating that HPV positivity may be transferred between partners (Gomousa-Michael et al., 1997) .
HPV prevalence at vaginal/vulvar sites
Two studies looked at women with vaginal and/or vulvar intraepithelial neoplasia or cancer (Tables 3 and 4 ) (Anastasiadis et al., 2000; Tsimplaki et al., 2012) . Both studies were limited because of the small and nonrandom population, as well as the fact that HPV testing methods were not documented in the article. Hence, we are not confident of the prevalence rates reported. Only one of these studies looked at age as an independent risk factor for HPV infection, and found that younger women with vulvar or vaginal neoplasia were at a higher risk for HPV infection .
Discussion
Although HPV has typically been associated with cervical cancer and diseases in women, emerging evidence has revealed the importance of HPV in other cancers in both sexes. A recent systematic review on HPV in head and neck cancer in Europe found that the prevalence of the virus in patients with relevant cancers was 40% (Abogunrin et al., 2014) . This represents a serious burden of disease, but also an opportunity for prevention. With the availability of a vaccine against HPV, it is possible to screen for and prevent HPV-related cancers at multiple anatomic sites.
Over half of the studies in this review investigated HPV prevalence in women at cervical sites alone (26/50), with four additional studies looking at cervical HPV prevalence as one of multiple anatomical sites. Therefore, the body of research on cervical HPV prevalence in Greece is well developed. Many of the large studies have found HPV prevalence rates among women to be quite high, ranging from 15.7 to 43.4% (Table 1) . However, studies conducted by Agorastos et al. (2004 Agorastos et al. ( , 2009 Agorastos et al. ( , 2014 report prevalence among women at a much lower rate, ranging from 2.5 to 5.9%. These studies tended to draw from multiple sites across a wide range of geographic locations, as opposed to a single large site or sites exclusively in Athens. This may provide a better representation of HPV prevalence among the general population of Greek women.
The development of technologies that allow a wider range of HPV strains to be typed has been significant. More recent studies have revealed high-risk strains, such as HPV types 31, 35, 51, and 59, present in the Greek population in addition to the well-known types 16 and 18. These additional high-risk types can also lead to the development of various cancers, and are not included in the HPV vaccines currently used by the Greek National Health program (Muñoz et al., 2003; European Centre for Disease Control and Prevention, 2015) . More data on the prevalence of these less-studied high-risk types would These studies do not breakdown HPV prevalence by sex. c A total of eight patients were unaccounted for in this study. These studies do not breakdown HPV prevalence by sex. These studies do not breakdown HPV prevalence by sex.
help guide screening and vaccination policy for women in Greece.
What is needed moving forward, as noted by the LYSISTRATA study, is to further investigate attitudes towards HPV vaccination among Greek women to expand vaccination programs and continue to increase prevention of cervical cancer (Agorastos et al., 2014) . The LYSISTRATA study reported that fear of adverse side effects was likely a major cause of the current low HPV vaccination rates among Greek women (Agorastos et al., 2014) . No data are available on vaccine uptake nationwide, but a recent study among female postsecondary students found that only 25% were vaccinated despite the fact that the vaccine is provided free of charge. Of those, 85% reported insufficient information or fear of adverse side effects as the major reason for not vaccinating (Michail et al., 2014) . More education on the HPV vaccine by both physicians and public health officials could serve to remedy this issue and lead to higher vaccine uptake among Greek women.
The remaining studies investigated HPV prevalence at a variety of anatomical sites in both men and women. Studies that investigated HPV prevalence at head and neck sites were the most numerous after cervical studies. Studying the epidemiology of HPV at these sites is particularly important given that previous studies have linked HPV infection to head and neck cancers (Kreimer et al., 2005) . However, there has only been one study in Greece with an asymptomatic screening population, and this study included a relatively small sample size (n = 169) (Lambropoulos et al., 1994) .The remaining head and neck HPV studies were single center studies and focused on patients with head and neck cancers ( Table 2) . As a result, the findings of these studies cannot be generalized to the population at large. The same applies for studies looking at anal and penile sites in Greece, which enrolled patients with existing anal and/or penile lesions or cancer (Labropoulou et al., 1994; Gomousa-Michael et al., 1997 Hadjivassiliou et al., 2007; Mavrogianni et al., 2011; Alexandrou et al., 2014) . An understanding of the epidemiology of HPV at these sites in asymptomatic individuals is needed to identify risk factors for infection and determine the costeffectiveness of vaccination in the general population.
Multicenter epidemiological studies investigating HPV prevalence at penile, anal, and head and neck sites should be conducted to fill this gap.
Overall, only seven studies included samples from anal or penile areas in men, with only two of these looking exclusively at HPV prevalence in men (Labropoulou et al., 1994; Gomousa-Michael et al., 1997 Hadjivassiliou et al., 2007; Yapijakis et al., 2008; Mavrogianni et al., 2011; Valari et al., 2011) . In light of the recent evidence supporting the role of HPV in cancers in men, there is an obvious gap in the data currently available on HPV prevalence in Greece (Dunne et al., 2006; Hebnes et al., 2014) . This is important since a metaanalysis looking specifically at men in Europe (including one study in Greece) found an overall HPV prevalence rate of 12.4% (Hebnes et al., 2014) . In addition, there is an even greater lack of knowledge on HPV prevalence in high-risk Greek men, such as MSM or HIV-positive men. Such studies would be useful in making appropriate public health plans for preventing associated morbidity and mortality from anal, penile, and oropharyngeal cancers in men.
As previously mentioned, several factors make this an important time to be examining HPV rates among both men and women in Greece. The high rates of smoking, recent economic crisis, and recent increase in HIV prevalence may all contribute to increased HPV risk (Kjellberg et al., 2000; HS, 2013; Ifanti et al., 2013; Antonsson et al., 2014; Roura et al., 2014) . In the postcrisis era people are more likely to be at higher risk for acquiring STIs (Tsang et al., 2015) . To assess these risks and develop future HPV and cancer prevention programs, better data on HPV prevalence both among the highest-risk populations and the general population is necessary.
Together, these factors highlight that it is critical to better understand the role of HPV in Greece. This systematic review has revealed that there are gaps in the reporting of HPV prevalence in Greece and we suggest that more research is needed on the prevalence of HPV in men at anal and penile sites. The current body of knowledge on HPV prevalence at oropharyngeal sites should also be expanded for both men and women. Filling these gaps will help inform public health programming and might aid in the detection and prevention of HPV-related cancers at oropharyngeal, anal, and penile sites. Moving forward, large, population-based studies of HPV prevalence at multiple anatomic sites are needed to accurately characterize HPV prevalence among men and women in Greece and develop appropriate public health programming to detect and prevent HPV-related cancers.
